Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 3/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 7/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12415413 | 0.82 | GRM5 (0.44) | KCNN4P2RX7MCHR1MAPTKMT2A | |
| SCHEMBL12415415 | 0.78 | MAPT (0.39) | GRIN1GRIN2BKCNN4MAPTKMT2A | |
| SCHEMBL2190611 | 0.75 | CYP3A4 (0.47) | ALDH1A1 | |
| SCHEMBL1728213 | 0.75 | CYP3A4 (0.47) | ALDH1A1 | |
| SCHEMBL1710957 | 0.75 | CYP3A4 (0.47) | ALDH1A1 | |
| SCHEMBL12415412 | 0.72 | ALDH1A1 (0.41) | P2RX7KMT2APOLBALDH1A1 | |
| SCHEMBL12415632 | 0.69 | MAPT (0.52) | KCNN4MAPTKMT2APOLBRAB9A | |
| SCHEMBL12415411 | 0.68 | HTT (0.41) | — | |
| SCHEMBL2187703 | 0.67 | CACNA1B (0.43) | MCHR1ALDH1A1 | |
| SCHEMBL2188512 | 0.67 | CACNA1B (0.43) | MCHR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CHAKRAVARTY PRASUN K | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, TRPA1, CACNA1D | GRIN1 260/4885GRIN2B 98/4885KCNN4 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.